Pablo G. Legorreta - 16 May 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: CEO, Chairman of the Board, Director
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta
Issuer symbol: RPRX
Transactions as of: 16 May 2025
Net transactions value: $0
Form type: 4
Filing time: 20 May 2025, 16:49:25 UTC
Previous filing: 14 May 2025
Next filing: 02 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Legorreta Pablo G.	CEO, Chairman of the Board, Director	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	20 May 2025	0001507678

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RPRX	Class A Ordinary Shares	Other	$0	+530,348	+151%	$0.000000	882,495	16 May 2025	Direct	F1
holding	RPRX	Class A Ordinary Shares						460,139	16 May 2025	By Legorreta Investments LLC
holding	RPRX	Class A Ordinary Shares						123,310	16 May 2025	By IRRA
holding	RPRX	Class A Ordinary Shares						118,500	16 May 2025	By SEP/IRA
holding	RPRX	Class A Ordinary Shares						1,040,410	16 May 2025	By Legorreta Children 2002 Trust
holding	RPRX	Class A Ordinary Shares						901,590	16 May 2025	By GST-Exempt Legorreta 2012 Family Trust
holding	RPRX	Class A Ordinary Shares						41,306	16 May 2025	By GST-Exempt Legorreta 2020 Family Trust
holding	RPRX	Class A Ordinary Shares						6,930	16 May 2025	By Spouse
holding	RPRX	Class A Ordinary Shares						292,190	16 May 2025	By Tata MC 35 Ltd.
holding	RPRX	Class A Ordinary Shares						10,000	16 May 2025	By Son
holding	RPRX	Class A Ordinary Shares						10,000	16 May 2025	By Daughter
holding	RPRX	Class A Ordinary Shares						600,000	16 May 2025	By Legorreta 2023 SR Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPRX	Class E Ordinary Shares	Award	$0	+13,356,742		$0.000000	13,356,742	16 May 2025	Class A Ordinary Shares	13,356,742	$0.000000	By PL RPH Holdings, LLC	F2, F3
transaction	RPRX	Option (Right to Buy)	Other	$0	+857,138		$0.000000	857,138	16 May 2025	Class A Ordinary Shares	857,138	$0.000000	By PL RPH Holdings, LLC	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the transfer to the Reporting Person by the RP Management Equity Incentive Plan Trust of Class A Ordinary Shares for no consideration.
F2	Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.
F3	Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.
F4	Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.